In 2025 Evogene conducted a comprehensive review of its technology, markets and capital allocation, choosing to concentrate exclusively on its proprietary ChemPass AI™ engine for small-molecule design. This shift streamlined operations to two high-impact markets—human therapeutics and agricultural ag-chemicals—while resizing the organization and establishing a dedicated business development team.

ChemPass AI™ generates novel molecules from a 38-billion-molecule universe, optimizing for multi-parameter success from inception. The platform’s competitive edge is reinforced by a second collaboration with Google Cloud and ongoing strategic engagements with Bayer and Corteva in ag-chem development.

Evogene divested non-core subsidiaries, selling Lavie Bio’s operations to ICL and licensing Biomica’s lead oncology candidate BMC128 to Lishan Pharmaceuticals, while retaining high-potential assets such as Casterra. These actions enhanced capital efficiency and focused resources on core growth drivers.

Multiple partner-led drug discovery programs progressed into testing in early 2026, reflecting ChemPass AI™’s ability to deliver development-candidate predictions. With four disclosed collaborations in human health and an expanding pipeline in agriculture, the company anticipates scaling activities and forging new partnerships to drive sustainable value.